Literature DB >> 2417697

Invasive and noninvasive implants in ovarian serous tumors of low malignant potential.

H Michael, L M Roth.   

Abstract

Ovarian serous tumors of low malignant potential ("borderline" serous tumors) are classified according to the histologic features of the primary ovarian tumor, without regard to any coexisting extraovarian disease. The peritoneal implants display a range of histologic appearances, ranging from benign glands (endosalpingiosis), to noninvasive papillary glandular proliferations resembling the ovarian neoplasms, to irregular glands associated with a desmoplastic stroma and having features of invasive disease. This review of 16 patients with histologically documented extraovarian tumor implants seen at Indiana University Medical Center, Indianapolis, and 13 patients whose tumor implants have been previously described in the literature indicates that the clinical stage of disease has much greater prognostic significance than does the implant histologic features. There is a tendency for patients with more advanced disease to have invasive implants. However, within a given clinical stage, disease progression or recurrence was not influenced by the presence or absence of invasive histologic characteristics in the tumor implants.

Entities:  

Mesh:

Year:  1986        PMID: 2417697     DOI: 10.1002/1097-0142(19860315)57:6<1240::aid-cncr2820570630>3.0.co;2-l

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  4 in total

1.  Non-ovarian peritoneal papillary serous carcinoma with high CA125 levels.

Authors:  H R Rosen; A C Rosen; J Preiser; M Stierer; M Klein; H Hanak
Journal:  Arch Gynecol Obstet       Date:  1992       Impact factor: 2.344

2.  DNA-cytophotometry and immunocytochemistry in ovarian tumours of borderline malignancy and related peritoneal lesions.

Authors:  B C Padberg; H E Stegner; S von Sengbusch; H Arps; S Schröder
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1992

Review 3.  Borderline ovarian tumors: a review of treatment.

Authors:  J T Chambers
Journal:  Yale J Biol Med       Date:  1989 Jul-Aug

Review 4.  The Putative Role of TP53 Alterations and p53 Expression in Borderline Ovarian Tumors - Correlation with Clinicopathological Features and Prognosis: A Mini-Review.

Authors:  Andrzej Semczuk; Marek Gogacz; Anna Semczuk-Sikora; Maciej Jóźwik; Tomasz Rechberger
Journal:  J Cancer       Date:  2017-08-22       Impact factor: 4.207

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.